Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 5, 2007, Pages 483-493

  Jones, Laura E ^a   Perelson, Alan S ^b  

^a Department of Obstetrics Gynecology   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

HIV; Latent reservoir; Transient viremia; Viral blips

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; INFECTION; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; PROGRAMMING LANGUAGES; RECURRENCE; RNA, VIRAL; VIRAL LOAD; VIREMIA; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 34548088101     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180654836     Document Type: Article

References (59)

1. Cohen Stuart JWT, Wensing AMJ, Kovacs C, et al. Transient relapses (blips) of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28:105-113.
2. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171-179.
3. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol. 2003;77:12165-12172.
4. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol. 2005;79:9625-9634.
5. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-829.
6. Gunthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response on persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000;181:47-62.
7. Jones LE, Perelson AS. Modeling the effects of vaccination on chronically infected HIV-positive patients. J Acquir Immune Defic Syndr. 2002;31:369-377.
8. Kolber MA, Gabr AH, De La RA, et al. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS. 2002;16:537-542.
9. Jones LE, Perelson AS. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol. 2005;67:1227-1251.
10. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus type 1 replication can be increased in the peripheral blood of seropositive patients after influenza vaccination. Blood. 1995;86:1082-1089.
11. Staprans SI, Hamilton B, Follansbee S, et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J Exp Med. 1995;182:1727-1737.
12. Brichacek B, Swindells S, Janoff EN, et al. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis. 1996;174:1191-1199.
13. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996;334:1222-1230.
14. Donovan RM, Bush CE, Markowitz NP, et al. Changes in virus load markers during AIDS-associated opportunistic diseases in human-immunodeficiency virus-infected persons. J Infect Dis. 1996;174:401-403.
15. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. J Immunol. 1996;157:1271-1278.
16. Mole L, Ripich S, Margolis D, et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 1997;176:766-770.
17. Bentwich Z, Maartens G, Torten D, et al. Concurrent infections and HIV pathogenesis. AIDS. 2000;14:2071-2081.
18. McLean AR, Nowak MA. Models of interactions between HIV and other pathogens. J Theor Biol. 1992;155:69-102.
19. Ferguson NM, deWolf F, Ghani AC, et al. Antigen-driven CD4+ T-cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1999;96:15167-15172.
20. Fraser C, Ferguson NM, de Wolf F, et al. The role of antigenic stimulation and cytotoxic T cell activity in regulating long-term immunopathogenesis of HIV: mechanisms and clinical implications. Proc R Soc Lond B Biol Sci. 2001;268:2085-2095.
21. Fraser C, Ferguson NM, Anderson RM. Quantification of intrinsic residual viral replication in treated HIV-infected patients. Proc Natl Acad Sci USA. 2001;98:15167-15172.
22. Di Mascio M, Percus JK, Percus OE, et al. Duration of an intermittent episode of viremia. Bull Math Biol. 2005;67:885-900.
23. Di Mascio M, Markowitz M, Louie M, et al. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol. 2004;78:10566-10573.
24. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science. 1996;271:1582-1586.
25. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature. 1997;271:1582-1586.
26. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol. 2002;2:28-36.
27. Di Mascio M, Ribeiro RM, Markowitz M, et al. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci. 2004;188:47-62.
28. Di Mascio M, Dornadula G, Zhang H, et al. In a subset of patients on highly active antiretroviral therapy plasma HIV-1 RNA can decay from 50 copies/ml to <5 copies/ml with a half-life of six months. J Virol. 2003;77:2271-2275.
29. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2001;2:415-422.
30. Van Stipdonk MJ, Lemmons EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol. 2001;21:29-70.
31. Wong P, Pamer EG. Antigen-independent CD8 T cell proliferation. J Immunol. 2001;166:5864-5869.
32. De Boer RJ, Perelson AS. Estimating division and death rates from CFSE data. J Comp Appl Math. 2005;184:140-164.
33. De Boer RJ, Ganusov VV, Milutinovic D, et al. Estimating lymphocyte division and death rates from CFSE data. Bull Math Biol. 2006;68:1011-1031.
34. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294.
35. Meaden ER, Hoggard PG, Newton P, et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother. 2002;50:583-588.
36. Perno C, Newcombe FM, Davis D, et al. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis. 1998;178:413-422.
37. Puddu P, Fais S, Luciani F, et al. Interferon-γ up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. Lab Invest. 1999;79:1299-1309.
38. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-1300.
39. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
40. Homann D, Teyton L, Oldstone MBA. Differential regulation of antiviral immunity results in stable CD8+ and declining CD4+ memory. Nat Med. 2001;7:913-919.
41. Blankson JN, Finzi D, Pierson TC, et al. Biphasic decay of latently infected CD4+ cells in acute human immunodeficiency virus type I infection. J Infect Dis. 2000;182:1636-1642.
42. Moore AL, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS. 2002;16:615-618.
43. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS. 2002;16:2035-2041.
44. Grueb G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967-1969.
45. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622.
46. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in persons receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-1613.
47. Dornadula G, Zhang H, Van Uitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627-1632.
48. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531-4536.
49. Siliciano JD, Kajdas J, Finzi D, et al. Long term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ cells. Nat Med. 2003;9:727-728.
50. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
51. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type-1 infected patients treated with suppressive antiretroviral therapy for five years. J Virol. 2003;77:11212-11219.
52. Chun T-W, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiretroviral therapy for extended periods of time continuously replenish their viral reservoir. J Clin Invest. 2005;115:3250-3255.
53. Gett AV, Hodgkin PD. A cellular calculus for signal integration by T cells. Nat Immunol. 2000;1:239-244.
54. De Boer RJ, Oprea M, Antia R, et al. Recruitment times, proliferation, and apoptosis rates during the CD8+ T cell response to LCMV. J Virol. 2001;75:10663-10669.
55. Ramratnam B, Bonhoeffer S, Binley J, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999;354:1782-1785.
56. De Boer RJ, Homann D, Perelson AS. Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol. 2003;171:3928-3935.
57. Callaway DS, Perelson AS. HIV-1 infection and low steady state viral loads. Bull Math Biol. 2002;64:29-64.
58. Zhang ZQ, Wietgrefe SW, Li Q, et al. Roles of substrate activity and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci USA. 2004;101:5640-5645.
59. Holte SA, Melvin AJ, Mullins JI, et al. Density-dependent decay in HIV-1 dynamics. J Acquir Immune Defic Syndr. 2006;41:266-276.